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Abstract: Following the epidemics of obesity due to the consumption of high-calorie diet and
sedentary lifestyle, nonalcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease
in Western countries. NAFLD is epidemiologically associated with metabolic syndrome and insulin
resistance, and in susceptible individuals it may progress to cirrhosis and hepatocellular carcinoma.
Genetic factors play a key role in NAFLD predisposition by interacting with nutritional and other
environmental factors. To date, there is no drug therapy for the treatment of NAFLD, and the main
clinical recommendation is lifestyle modification. In the last years, nutrigenomics is promoting an
increased understanding of how nutrition affects the switch from health to disease by altering the
expression of an individual’s genetic makeup. The present review tries to summarize the most recent
data evidencing how the interactions between nutrients and genetic factors can influence NAFLD
development. The final goal should be to develop tools to quantify these complex interactions.
The definition of a “nutrigenomic risk score” for each individual may represent a novel therapeutic
approach for the management of NAFLD patients.
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is defined by fat accumulation exceeding 5% of liver
weight not explained by at-risk alcohol intake [1]. NAFLD is epidemiologically associated with
metabolic syndrome and insulin resistance (IR) [2,3]. Following the epidemic of obesity due to the
consumption of high-calorie diet and sedentary lifestyle, NAFLD is becoming a serious global health
problem, representing the leading cause of liver disease [4–6]. NAFLD defines a wide pathological
spectrum, ranging from indolent liver fat storage, which may remain uncomplicated to nonalcoholic
steatohepatitis (NASH) characterized by hepatocellular damage, lobular necroinflammation, and the
activation of fibrogenesis [7,8]. NASH potentially predisposes to liver cirrhosis and hepatocellular
carcinoma (HCC), and is projected to become the first cause of liver-related morbidity and mortality in
Western countries within ten years [9].
A growing body of evidence indicated that NAFLD develops as a result of a complex interaction
between genetic susceptibility and other environmental factors [10], typically hypercaloric diet and
physical inactivity. Furthermore, NAFLD development and progression is modulated by epigenetic
factors such as liver-specific DNA-methylation and microRNAs, which regulate the liver transcriptome.
There is currently no drug therapy for the treatment of NAFLD, and the mainstay management
of the disease is lifestyle modification. The interface between the nutritional environment and
cellular/genetic processes is being referred to as nutritional genomics or “nutrigenomics” [11]. In the
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last years, nutrigenomics has contributed to the understanding of how nutrition affects the switch
from health to disease by modulating the expression of an individual’s genetic makeup.
In this review, we focus upon the interaction of genetic background and diet with regard to the
development and progression of NAFLD, which can be considered a good candidate for nutrigenomic
studies. Indeed, individuals vary in their nutrients requirement and response to diet according to their
genetic features, suggesting that personalized nutrition may represent an individualistic therapeutic
approach to the disease, with risk being modulated by nutritional, lifestyle, and genetic influences.
2. Pathophysiology of NAFLD
Hepatic fat accumulation results from an imbalance between the uptake and synthesis of fatty
acids on one hand, and their utilization and secretion on the other hand. Esterification in the form
of triglycerides (TGs) in hepatocellular lipid droplets represents the safest way to store fatty acids
in the liver [2]. Excess hepatocellular TG derives from several sources, including dietary fatty acids,
increased peripheral lipolysis due to adipose tissue insulin resistance, and elevated hepatic de novo
lipogenesis (DNL) due to hyperinsulinemia [10,12,13]. A relative reduction of lipid secretion through
very-low-density lipoproteins (VLDL) and of mitochondrial oxidation with the advent of oxidative
damage are also involved in hepatic fat accumulation [13].
The multiple hit hypothesis proposed that TG accumulation sensitizes the liver to second insults,
which are represented by (a) direct lipotoxicity and endoplasmic reticulum stress, (b) hepatocellular
oxidative stress secondary to free radicals produced during β- and ω-oxidation of free fatty acids
(FFAs), (c) inflammation triggered by endotoxin engaging Toll-like receptor-4 in Kupffer cells and
hepatocytes due to increased intestinal permeability and to qualitative and quantitative changes in
gut microbiota [14,15], (d) insulin resistance and altered profile of adipokines [16], (e) activation and
senescence of hepatic stellate cells [17]. All these conditions lead to hepatic inflammation, cellular
damage, and the activation of fibrogenesis. However, other organs (e.g., the adipose tissue, muscle,
and intestine) are involved in the pathogenesis of NAFLD, which can thus be defined as a systemic
metabolic disorder [18].
3. Genetics of NAFLD
Although many individuals share environmental risk factors such as obesity, not all at risk subjects
develop fatty liver, suggesting that the genetic background plays a significant role in determining this
condition. Epidemiological, familial, and twin studies [19,20] support a strong heritability component
in NAFLD and NASH [21]. Indeed, there is a huge inter-ethnic variability in the predisposition towards
NAFLD [4].
The rs738409 C > G variant in patatin-like phospholipase domain-containing 3 (PNPLA3)— encoding
for the amino acid substitution I148M—has been identified as a major determinant of hepatic fat
content [22,23]. The size effect of the I148M variant on the risk of NAFLD is the strongest ever reported
for a common variant, modifying the genetic susceptibility of NAFLD [24,25] and also determining liver
disease severity and the progression of NAFLD [23,24,26]. The polymorphism exerts its detrimental
activity by leading to PNPLA3 accumulation at the surface of hepatocellular lipid droplets, where it likely
inhibits the activity of other lipases, determining reduced TG turnover and dismissal [27]. Accumulation
of the mutated I148M protein is triggered by acquired factors. Indeed, PNPLA3 is nutritionally regulated
at the transcriptional level in response to increased insulin levels by sterol regulatory element-binding
protein (SREBP)-1c through carbohydrate-mediated activation of liver X receptor/retinoid X receptor
(LXR/RXR). Furthermore, fatty acids can inhibit PNPLA3 protein degradation [28–30]. As a consequence,
a significant interaction exists between the effect of adiposity on the phenotypic expression of the PNPLA3
mutation and the risk of NAFLD and cirrhosis [31]. This represents a clear demonstration of a gene↔*
environment interaction in the pathogenesis of a complex disease.
The rs58542926 C > T genetic variant of the transmembrane 6 superfamily member 2 gene
(TM6SF2), encoding the E167K variant, is another determinant of hepatic triglyceride content [32]
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and the full spectrum of liver damage linked to hepatic fat accumulation, including NASH,
necroinflammation, and fibrosis. The protein is involved in VLDL lipidation and secretion, and
the mechanism of the association is related to the retention of lipids within intracellular lipid
droplets [32,33].
Variation in the GCKR (glucokinase regulatory gene) locus has been associated with fasting
triglycerides levels [34–37] and NAFLD [38–41]. GCKR regulates DNL by controlling the influx of
glucose in hepatocytes. A common missense loss-of-function GCKR mutation (rs1260326), encoding
for the P446L protein variant, may represent the causal variant underlying the association with hepatic
fat accumulation [37,42,43]. The P446L variant indeed affects GCKR’s ability to negatively regulate
glucokinase in response to fructose-6-phosphate, thereby determining constitutive activation of hepatic
glucose uptake [39]. This leads to decreased circulating fasting glucose and insulin levels, but on the
other hand it would lead to increased glycolysis and the production of malonyl-CoA which favors
hepatic fat accumulation by serving as a substrate for lipogenesis and by blocking fatty acid oxidation.
The rs641738 C > T variant linked to the 3’ untranslated region of the MBOAT7 (membrane
bound O-acyltransferase domain-containing 7 gene) was recently associated with the risk of NAFLD,
inflammation, and fibrosis by reducing protein expression and phosphatidyl-inositol desaturation in
hepatocytes [44].
Finally, case–control studies demonstrated a role of other genetic variants implicated in inflammation,
insulin signaling, oxidative stress, and fibrogenesis in NAFLD progression (reviewed in [45]).
4. Nutrients and NAFLD
Diet is an important contributor to the pathogenesis of NAFLD. Excessive energy intake results
in excess adiposity, insulin resistance, and the consequent inappropriate release of fatty acids into
the circulation. Dietary fat represents the primary source of adipose tissue fatty acids, which are
subsequently released and re-esterified in the liver [46]. The composition of diet and the nature of
fatty acids may also impact hepatic DNL by directly regulating the expression of genes involved in
fatty acid synthesis. It has been established that—at least in animal models—polyunsaturated fatty
acids (PUFAs) down-regulate sterol regulatory element binding protein-1c (SREBP-1c) [47], whereas
saturated fatty acids (SFAs) stimulate its expression.
NAFLD patients tend to have a dietary pattern characterized by a higher consumption of SFAs,
cholesterol, and fructose, and lower ingestion of PUFAs and antioxidants (vitamin C and E) [48]. It is
possible that altering dietary macronutrient composition, which addresses specific molecular pathways
and modifies gene and protein expression, modulates the clinical outcome.
4.1. Saturated and Unsaturated Fatty Acids
The consumption of diets rich in saturated fatty acids triggers DNL. The action of SFAs on
hepatic lipid metabolism is influenced by the peroxisome proliferator-activated receptor (PPAR)-γ
coactivator-1beta (PGC-1β). A high-fat diet enriched with SFAs stimulates liver PGC-1β, which
coactivates SREBP-1c and enhances its transcriptional activity in lipogenic genes, such as stearoyl-CoA
desaturase-1 (SCD-1), fatty acid synthase (FAS), and diacylglycerol acyltransferase (DGAT) [49].
Dietary patterns enriched in SFAs have also been associated with a higher expression of the unfolded
protein response (UPR)-related components, all elicited by endoplasmic reticulum stress. Moreover,
an increase in caspase 3 activity was also observed [50].
The ingestion of monounsaturated fatty acids (MUFAs) lowers cardiovascular risk and improves
lipid profile. Replacement of SFAs with MUFAs ameliorates serum glucose levels and blood
pressure [51]. MUFAs inhibit the oxidation of LDL-cholesterol and decrease the serum level of
triglycerides by activation of peroxisome proliferator-activated receptor α (PPARα). PUFAs—in
particular docosahexaenoic acid (DHA)—are long-chain n-3 fatty acids that reduce TG accumulation
and improve hepatic steatosis [52]. PUFAs might prevent NAFLD by activation of peroxisome
proliferator-activated receptors (PPARs) and inhibition of SREBP-1c. PPARs are the most extensively
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characterized nuclear receptors that are regulated by fatty acids [53]. There are three major isoforms
of PPARs: PPARα, PPARβ, and PPARγ, with PPARα being the predominant isoform in liver. Ligand
activation of PPARα is associated with transcriptional up-regulation of a wide range of genes for
proteins associated with fatty acid oxidation and lipoprotein metabolism [52].
4.2. Carbohydrates
Carbohydrates are the main substrate that drive DNL in the liver and the adipose tissue.
In particular, the intake of sucrose-sweetened beverages has been associated with a higher amount
of visceral adipose tissue (VAT) and liver fat accumulation compared with milk, diet cola, and
water [54]. A study which compared the consumption of fructose-sweetened with glucose-sweetened
beverages revealed that mainly fructose-containing drinks increase visceral adipose volume, promote
DNL, and decrease insulin sensitivity in overweight/obese subjects [55]. Fructose consumption
induces hepatic lipid accumulation by (a) activation of lipogenic gene expression and (b) direct flow
of fructose carbon into the glycolytic pathway [56]. Fructose but not glucose ingestion activates
hepatic carbohydrate-responsive element-binding protein (ChREBP), which regulates glycolytic and
lipogenic gene expression programs [57]. Moreover, dietary fructose impairs the insulin signaling
pathway by increasing c-Jun N-terminal kinase (JNK) activity and insulin receptor substrate 1 (IRS-1)
phosphorylation [58]. Finally, elevated dietary fructose intake facilitates bacterial overgrowth in the
small intestine, accompanied by heightened intestinal permeability. It increases endotoxin levels in the
portal vein and contributes to the mechanism of NAFLD [59].
4.3. Proteins
Although the effects of dietary protein on hepatic lipids is not clear, clinical trials show that protein
intake has a beneficial impact on the course of NAFLD [60]. Experiments in rodents demonstrated
that a high-protein and low-carbohydrate diet reduces adipose tissue deposition, improves glucose
homeostasis, and decreases steatosis by inhibition of DNL [61]. Dietary protein has a beneficial effect
on glucose metabolism and decreases insulin output. Protein intake is essential for the regeneration of
hepatocytes and supplies crucial amino acids for the inclusion of fat into lipoproteins for liver export,
thus preventing steatosis [62].
Moreover, as amino acid catabolism is an energy-requiring process, a higher protein consumption
might trigger hepatic lipid oxidation through an increase in hepatic energy expenditure [63].
4.4. Metals and Other Dietary Components
NAFLD is also characterized by a derangement in the homeostasis of metals, possibly reflecting
an increased oxidative stress and an inflammation condition. In particular, it has been demonstrated
that iron and copper dys-homeostasis can contribute to NAFLD pathogenesis.
Iron (Fe) is an essential nutrient required for erythropoiesis and multiple cellular metabolic
functions. However, an excess of iron may be detrimental, mostly via the formation of reactive oxygen
species, which may lead to severe organ damage. Iron perturbations are frequently observed in
patients with NAFLD. Hepatic iron overload in conjunction with metabolic syndrome is commonly
observed, and has been termed dysmetabolic iron overload syndrome (DIOS). Increased ferritin levels
are usually associated with NASH and the severity of liver damage, whereas in patients with mild
iron overload, iron depletion may decrease insulin resistance and liver damage [64,65]. Moreover, iron
depletion up-regulated glucose uptake and increased insulin receptor expression and signaling in
hepatocytes in vitro and in vivo [66], whereas dietary iron supplementation induced insulin resistance
and dyslipidemia [67]. To investigate the mechanisms underlying iron accumulation in NAFLD
patients, we recently examined the effect of fatty acids on hepatic iron metabolism. The exposure
of hepatocytes to FFAs, leading to steatosis, was associated with a subversion of iron metabolism
characterized by increased expression of transferrin receptor and the facilitation of iron storage [68].
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Copper is known to be essential for many physiologic processes, such as antioxidant defense,
lipid peroxidation, and mitochondrial function. A copper (Cu)-restricted diet induced NAFLD in
animal models [69]. In addition, hepatic Cu deficiency is observed in human NAFLD and is associated
with steatosis, NASH progression, and insulin resistance [70,71]. Additionally, NAFLD patients
with low copper levels have increased iron stores [70]. In experimental models, dietary copper
deficiency determined increased hepatic iron content as well as steatosis and insulin resistance [71].
Intestine-specific genetic inactivation of high-affinity copper import in mice also resulted in hepatic
iron overload [72]. Interestingly, fructose feeding exacerbates complications of copper deficiency.
In rats, fructose consumption impaired copper status and precipitated copper deficiency, possibly
inhibiting its absorption through the intestinal epithelium.
Moreover, dietary copper deficiency and fructose feeding work together to exacerbate liver
damage and accelerate hepatic fat accumulation [69,73]. Hepatic carnitine palmitoyltransferase 1 CPT-1
expression was significantly inhibited whereas FAS was markedly upregulated [69] in copper-deficient
rats fed with fructose. Finally, rats fed either high-sucrose or low-copper diet had increased hepatic
inflammation and fibrogenesis and hepatic stellate cell activation, while the combination of dietary
factors induced fasting hepatic insulin resistance and liver damage [74].
5. Epigenetics in NAFLD
The emerging field of epigenetics, a heritable but reversible phenomenon that allows for
fine-tuning gene expression without altering DNA sequence, provides a new perspective on the
pathogenesis of NAFLD [75]. The epigenetic modulation of gene expression includes chromatin
remodeling (histone modifications), DNA methylation, and regulation of RNA processing, stability, and
translation through specific binding of small RNA molecules (microRNAs). Epigenetic modifications
are known to be involved in hepatic lipid metabolism, insulin resistance, mitochondrial dysfunction,
and oxidative stress—all of which contribute to NAFLD development and progression [76,77]
There has been considerable progress in understanding epigenetic mechanisms by which the fetal
liver might be “primed” by gestational over-nutrition, and epigenetic modifications can be inherited
from parents to their offspring. For example, increased methylation leading to down-regulation of
PGC1α and mitochondrial biogenesis has been reported in patients with NAFLD [78]. In addition, fetal
exposure to high fat diet (HFD) has been associated with histone modifications of the phosphoenol
pyruvate carboxy kinase 1 gene (PCK1), the rate-limiting enzyme in the gluconeogenic pathway.
These data suggest that epigenetic mechanisms prime offspring liver for increased hepatic glucose
production [79]. Moreover, the livers of offspring mice exposed to maternal HFD were hypomethylated
at the Cdkn1a gene, which codes for a cell cycle inhibitory protein, impairing the regenerative capacity
and response to damage [80].
DNA methylation is considered a key factor in the process leading from simple steatosis to NASH,
and it may be modulated by dietary deficiency of fundamental methyl donors such as betaine, choline,
and folate [81]. Supplementation of betaine is associated with a reduced methylation of the promoter of
microsomal triglyceride transfer protein (MTTP), involved in VLDL lipidation, consequently promoting
TG export from the liver [82], whereas folate deficiency induces triglycerides accumulation in the liver
by influencing the expression of genes involved in fatty acids synthesis [83].
Moreover, in a study that included obese patients with NAFLD and healthy controls, NAFLD-specific
methylation differences were seen for nine genes coding for key enzymes catalyzing the initial steps in
glucose, lipid, acetyl-CoA, and oligosaccharide synthesis and pathway members of insulin signaling.
These NAFLD-specific methylation changes were partially reversible after bariatric surgery [84].
6. A Role for Microbiota?
Each individual contains about 1.5–2 Kg of micro-organisms (bacteria, fungi, viruses, and
bacteriophages) within the gut. The intestinal microbiota contains >100-fold genes than the human
genome, which are responsible for the production and modifications of a wide range of circulating
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metabolites, regulating the function of organs (reviewed in [85]). Human diseases are associated with
modification of the human microbiota, and the diet is able to profoundly reshape the microbiotal
composition within hours. It has already been demonstrated that the beneficial effect of some drugs
(e.g., metformin) is partly mediated by their effect on the microbiota [86]. Therefore, it is likely that the
effect of diet on the risk of NAFLD is partly mediated by alterations of the microbiota.
Intake of alcohol or a diet rich in saturated fatty acids, cholesterol, and fructose impairs the
intestinal barrier by weakening the mucus-associated defense, impairing tight junction function
and causing intestinal inflammation with subsequent translocation of bacterial pathogens into the
bloodstream and to the liver. Several lines of evidence suggest that endotoxemia is involved
in the pathogenesis of NAFLD/NASH. Endotoxin induces systemic inflammation and hepatic
necroinflammation mainly through its action on toll-like receptor 4 (TLR4), and NAFLD/NASH
patients have increased endotoxin levels in the blood. Indeed, patients with NAFLD have significantly
increased gut permeability [15] and a higher prevalence of small intestine bacterial overgrowth
compared to healthy controls, which in turn increase the absorption of endotoxin. Specifically,
a dysbiotic microbiome is often observed among obese individuals and is considered to be one
of the major risk factors for NAFLD [87]. Both obesity and NAFLD are associated with a higher
proportion of Gram-negative bacterial species in the gut microbiome, and microbial populations
of NASH patients have been suggested to have a higher ability to produce alcohol [88]. Given the
association between specific microbial population and NAFLD, the development of a specific metabolic
diagnostic profile could possibly represent a non-invasive therapeutic approach [89,90], and may be
also useful for monitoring fibrosis stage.
7. Interaction between Genetic and Nutritional Factors
The PNPLA3 I148M variant represents a first and until now almost unique example of a genetic
factor for which a clear interaction between the gene and environment has been robustly demonstrated.
The PNPLA3 I148M variant interacts with environmental stressors such as obesity [31,91] and alcohol
consumption [92], which induce fatty liver. Similarly, individuals who carry the I148M variant are
more susceptible to increased fat content when dietary carbohydrate intake—specifically sugar—is
high [93]. A nutrigenetic analysis with the I148M variant in Hispanic children revealed that hepatic
TG accumulation was related to carbohydrate and sugar intake in the homozygous 148M/M group,
whereas no effect was observed in I/I and I/M individuals. In Italian adolescents, the 148M variant
interacted with dietary intake of fructose-sweetened beverages in determining NAFLD [94,95]. These
results are consistent with the notion that the reduced capacity of subjects with the 148M/M genotype
to hydrolyze TG in the liver would be exacerbated in the context of high dietary sugar, because
carbohydrate-mediated up-regulation of PNPLA3 would favor the accumulation of the pathological
protein on the surface of lipid droplets, resulting in the inhibition of other lipases, mainly PNPLA2
(Figure 1). Consistently, a short-term dietary intervention study provided evidence that a hypocaloric
and low-carbohydrate diet reduces hepatic fat to a greater extent in PNPLA3 148M/M carriers as
compared to wild-type individuals, despite similar weight loss in both genotype groups.
In addition, hepatic fat accumulation could be modulated by the interaction between PNPLA3
I148M and dietary omega 6/omega 3 PUFA [96]. The I148M variant has decreased activity in
hydrolyzing the n-9 fatty acids [97]. The n-9 represent the most common fatty acids in the diet,
but they are also synthesized starting from n-6. It could be speculated that the newly-synthetized TGs
tend to accumulate in the liver in patients carrying the 148M risk variant, leading to steatosis. In the
meantime, the excess of n-6 not incorporated in TG will be utilized as substrate for the synthesis of
proinflammatory species, triggering NASH [96]. Recently, data from the WELCOME trial revealed
that in patients with NAFLD the PNPLA3 148M/M genotype was associated with higher liver fat
percentage and lower DHA tissue enrichment and reduced amelioration of aminotransferases after
DHA+EPA supplementation for 15–18 months [98]. Consistently, in a randomized trial of short-term
DHA supplementation in children with NAFLD, carriage of the 148M risk variant reduced the beneficial
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effect on liver enzymes and circulating lipids [99]. These results suggest that PNPLA3 I148M is involved
in omega-3 fatty acids mobilization in the liver, and subjects with PNPLA3 148M/M genotype have
lower levels of DHA [96]. Additionally, omega-3 fatty acids decrease the expression of SREBP1c [100],
and carriers of the PNPLA3 148M allele tend to have decreased DNL as a feed-back mechanism to
avoid excessive lipid accumulation [101]. Thus, it is possible that the lack of response to omega-3
fatty acids supplementation in decreasing liver fat percentage in subjects with PNPLA3 I148M/M is
explained by the fact that these subjects already have low levels of DNL.Int. J. Mol. Sci. 2017, 18, 1534 7 of 15 
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Initial evidence has been gathered on the interaction between GCKR variation and diet in the
pathogenesis of dyslipidemia, although no data are yet available specifically for NAFLD. GCKR
variation determines higher fasting TG levels and higher absolute plasma postprandial TG and
VLDL-cholesterol levels following a fat-meal challenge [102,103]. Supporting the presence of gene–diet
interaction, in metabolic syndrome individuals participating to the LIPGENE study it has been reported
a statistically significant association between GCKR rs1260326 polymorphism and plasma omega-3
fatty acids modulating insulin resistance and inflammatory markers. Moreover, an interaction has
been demonstrated between the P446L GCKR variant and Mediterranean diet on circulating TG
concentrations. Indeed, adherence to this dietary pattern blunted the negative effect of the risk 446L on
circulating TG, likely reflecting the activation of DNL [104]. Consistent with these latter findings, the
influence of GCKR genotype on serum cholesterol was reported to depend on the MUFA: SFA ratio in
the diet [105].
8. Future Perspectives
The field is clearly only in its early stages, and in order to develop a full nutrigenomic approach
to the management of NAFLD, key information is still missing.
In particular, large well-characterized cohorts with contemporary determination of (a) nutritional
(b) genomics (and possibly epigenetics, transcriptomics, and proteomics) (c) microbiota composition
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(d) hepatic fat and liver damage assessment will be needed together with long-term follow-up of
patients. The integration of this information could be used to define biomarkers and to develop tools
to calculate a NAFLD risk score by changing our ability to control or cure the disease.
To apply these findings to the treatment of patients with NAFLD, randomized controlled trials
aimed at the study of the interaction between diet and genetic/epigenetic factors on health-related
outcomes will have to be conducted, in order to optimize the individual’s response to the intervention.
9. Conclusions
NAFLD is becoming a serious global health problem, representing the leading cause of liver
disease. To date there are no approved drugs for the treatment of NAFLD, and the main clinical
recommendation as an initial step is lifestyle modification, that is reduced caloric intake and physical
exercise. Supporting a key role of gene–diet interaction in NAFLD development, it is important to
understand how dietary composition, which influences specific molecular pathways and modifies
gene and protein expression, could modulate the clinical outcome. Personalized dietary intervention
based on the reduction of carbohydrates and sugar intake in genetically predisposed individuals
with the PNPLA3 at-risk genotype may lead to more effective clinical outcomes for NAFLD patients.
Since an individual’s genetic makeup influences how nutrients are assimilated, stored and excreted,
personalized nutrition which takes into account the genetic features of patients could have immediate
potential for clinical translation, representing an individualized therapeutic approach to the disease
(Figure 2).
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intervention based on knowledge of nutritional requirement, nutritional status, and genetic makeup 
(personalized medicine) can be used in the management of NAFLD patients. 
Figure 2. A nutrigenomic approach for nonalcoholic fatty liver disease (NAFLD). Dietary intervention
based on knowledge of nutritional requirement, nutritional st us, and genetic makeup (personalized
medicine) can be used in the management of NAFLD patie ts.
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